Sonia Partap

Clinical Professor, Neurology Clinical Professor (By courtesy), Neurosurgery Clinical Professor, Pediatrics

Clinical Focus

Pediatric Neuro-Oncology
Neurology with Special Qualifications in Child Neurology

Academic Appointments

Clinical Professor, Neurology
Clinical Professor (By courtesy), Neurosurgery
Clinical Professor, Pediatrics
Member, Maternal & Child Health Research Institute (MCHRI)

Administrative Appointments

Pediatric Neuro-Oncology Fellowship Director, Stanford (2012 - Present)
Program Director, Neuro-Oncology Fellowship (UCNS), Stanford (2020 - Present)

Boards, Advisory Committees, Professional Organizations

Councilor of the West, Child Neurology Society (2020 - 2022)
Pediatric Representative, American Academy of Neurology, Section of Neuro-Oncology (2015 - Present)
Member, Executive Committee, Section of Neurology, American Academy of Pediatrics (2012 - 2018)
Treasurer (elect), Brain Tumor Epidemiology Consortium (2012 - 2014)

Professional Education

Board Certification: American Board of Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology (2007)
Medical Education: University of Missouri Kansas City School of Medicine Registrar (2000) MO
Residency: Brown University Hospitals (2002) RI
Residency: Childrens Hospital and Regional Medical Center Fellowships (2006) WA
Fellowship:, Packard Children's & Stanford Hospital, Neuro-Oncology (2007)
Masters:, Stanford University, Epidemiology (2009)
Board Certification: American Board of Pediatrics, Pediatrics (2007)
Board Certification: United Council for Neurologic Subspecialties, Neuro-Oncology (2011)

Contact

Administrative Contact Julie Ng Administrative Assistant julieng@stanford.edu Tel: 650-736-0885

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Pediatric Oncology Clinic 725 Welch Rd Ste 160 Palo Alto CA 94304 Tel: (650) 497-8953 Fax: (650) 497-8101

Additional Clinical Info

Stanford Medicine Children's Health

Current Research and Scholarly Interests

My research interests involve the epidemiology, treatment and diagnosis of pediatric and young adult brain tumors. I am also interested in long-term neurologic effects and designing clinical trials to treat brain and spinal cord tumors.

Clinical Trials

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Not Recruiting
More
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Recruiting
More
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors Recruiting
More
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Recruiting
More
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Lead Sponsor
Stanford Investigators
- Michelle Monje
- Sonia Partap
View full details
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) Recruiting
More
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Lead Sponsor
Stanford Investigators
View full details
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Recruiting
More
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system, and may interfere with the ability of tumor cells to grow and spread.
Lead Sponsor
Stanford Investigators
View full details
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Not Recruiting
More
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: - To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. - To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. - To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. - To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: - WNT (Strata W): positive for WNT biomarkers - SHH (Strata S): positive for SHH biomarkers - Non-WNT Non-SHH, Failed, or Indeterminate (Strata N): negative for WNT and SHH biomarkers or results are indeterminable Participants will then be assigned to a clinical risk group (low, standard, intermediate, or high) based on assessment of: - How much tumor is left after surgery - If the cancer has spread to other sites outside the brain [i.e., to the spinal cord or within the fluid surrounding the spinal cord, called cerebrospinal fluid (CSF)] - The appearance of the tumor cells under the microscope - Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)

Stanford is currently not accepting patients for this trial. For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Lead Sponsor
Stanford Investigators
View full details
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma Not Recruiting
More
This multi-institutional study will prospectively collect tumor and constitutional tissue samples from patients with diffuse brainstem glioma and other types of brainstem gliomas either during therapy or at autopsy to perform an extensive analysis of genetic and molecular abnormalities in these tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Michelle Monje, .
Lead Sponsor
Stanford Investigators
- Paul Graham Fisher, MD
- Sonia Partap
View full details

All Publications

Profiles With Related Publications

close
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma
Clinical Focus
Cancer > Lymphoma, Burkitt's Lymphoma, Hodgkin's Disease, Investigational Therapeutics, Lymphoma , Mycosis Fungoides, Non-Hodgkin's Lymphoma, Oncology (Cancer), Plasmacytoma, Waldenstrom's Macroglobulinemia , Medical Oncology
Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

664 Total Publications
close
Patrick Barnes

Professor of Radiology (Pediatric Radiology) at the Stanford University Medical Center, Emeritus
Research Interests
Advanced imaging, including magnetic resonance imaging, of injury to the developing central nervous system; including fetal, neonatal, infant and young child; and, including nonaccidental injury (e.g. child abuse).

See Biosketch for details.

193 Total Publications
close
Melissa L Bondy

Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics

443 Total Publications
close
Saurabh Dahiya, MD, FACP

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Clinical Focus
Blood and Marrow Transplantation, Cellular Therapy, Hematology

82 Total Publications
close
Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus
Research Interests
Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

171 Total Publications
close
Sarah S. Donaldson, MD

Catharine and Howard Avery Professor in the School of Medicine, Emerita
Research Interests
Combined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases

306 Total Publications
close
Nancy Fischbein

Professor of Radiology and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) , of Neurology, of Neurosurgery & of Radiation Oncology
Clinical Focus
Diagnostic Neuroimaging

215 Total Publications
close
Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Clinical Focus
Cancer > Neuro Oncology, Neurology - Child Neurology, Neuro-Oncology, Neurology
Research Interests
Clinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.

276 Total Publications
close
Seunggu Jude Han, MD

Clinical Associate Professor, Neurosurgery
Clinical Focus
Neurological Surgery

130 Total Publications
close
Steven Hancock, MD

Emeritus Faculty-Med Ctr Line, Miscellaneous

188 Total Publications
close
Melanie Hayden Gephart

Professor of Neurosurgery and, by courtesy, of Neurology
Clinical Focus
Neurosurgery

155 Total Publications
close
Michael Jeng

Professor of Pediatrics (Hematology/Oncology)
Clinical Focus
Hematology, Pediatric, Vascular anomalies, Histiocytic disorders, Langerhans cell histiocytosis, Hemophagocytic Lymphohistiocytosis, Pediatric Hematology-Oncology
Research Interests
Research interests focus on: 1) histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH), and 2) vascular anomalies and malformations.

104 Total Publications